Research-use information only. This page summarises published laboratory findings on the individual components of the KLOW blend. None of these compounds are licensed medicines in the UK, none are approved for human consumption, and nothing here is medical or dosing advice.
KLOW is a four-component research blend combining GHK-Cu, BPC-157, TB-500 and KPV in a single 80mg vial. Each component acts through a distinct and independently documented mechanism — copper-tripeptide matrix remodelling, pentadecapeptide angiogenic signalling, actin sequestration, and tripeptide immune modulation respectively. This page sets out what the research record says about each, and why they are studied together.
What is in the KLOW blend
The name is an acronym of its components. The 80mg total is distributed across four sequences with quite different molecular sizes and mechanisms:
- GHK-Cu — a copper-binding tripeptide (glycyl-L-histidyl-L-lysine) complexed with copper(II)
- BPC-157 — a synthetic pentadecapeptide derived from a sequence in human gastric juice
- TB-500 — the synthetic fragment corresponding to the active region of thymosin beta-4
- KPV — a tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-MSH
Why these four are studied together
The research rationale for combining them is mechanistic non-overlap. Each addresses a different stage or axis of the tissue-repair literature rather than duplicating the same pathway:
- GHK-Cu — studied for extracellular matrix remodelling, collagen and glycosaminoglycan synthesis, and antioxidant gene expression. Copper delivery is itself part of the proposed mechanism. See our GHK-Cu research reference.
- BPC-157 — studied for angiogenic signalling via VEGFR2 and the FAK-paxillin pathway, and for nitric oxide system interaction. See the BPC-157 research hub.
- TB-500 — studied for G-actin sequestration and the resulting effects on cell migration. See TB-500 and wound healing research.
- KPV — studied for anti-inflammatory activity, reported in the literature to act intracellularly on NF-κB signalling rather than through melanocortin receptor binding, despite being an alpha-MSH fragment.
In short: matrix, vasculature, cell migration, and inflammatory tone. The combination is studied because these are four separable variables, not because their effects are known to be additive — a distinction the literature does not currently resolve.
What the evidence does and does not support
This is worth stating plainly. The individual components each have their own preclinical evidence base, of varying depth and quality. What does not exist is a substantial body of controlled research on this specific four-way combination at these specific ratios. Studies of the components in isolation cannot be assumed to predict combined behaviour, and possible interactions — competitive, synergistic or neutral — have not been systematically characterised.
Researchers designing protocols around a blend should treat that gap as a limitation of the study design, not an inconvenience to work around.
Reconstitution and handling
Because a blend contains multiple sequences of differing stability in a single vial, the least stable component governs the handling protocol for the whole preparation. Reconstitution is with bacteriostatic water; the reconstituted solution is refrigerated. GHK-Cu in particular is light-sensitive as a copper complex.
For volume and concentration calculations across a multi-component vial, use our peptide reconstitution calculator. Note that dosing a blend by total milligrams does not tell you the quantity of any individual component — that requires the stated ratio.
Blend versus individual vials
The research trade-off is straightforward. A blend fixes the ratio between components; individual vials allow each to be varied independently. For any study where the contribution of a single component is a variable of interest, separate vials are the appropriate choice. A blend is appropriate where the combination itself is the object of study.
Individual components are available separately: GHK-Cu, BPC-157, and the BPC-157 and TB-500 combination.
The UK regulatory position
None of the KLOW components are licensed medicines in the UK, and none are approved for human consumption. Lawful supply is for laboratory research only, correctly labelled. Blends carry a particular verification burden: a Certificate of Analysis should confirm the identity and purity of each component, not merely the total mass of the vial. Our quality-standards SOP sets out the testing applied to every batch.
Frequently asked questions
What does KLOW stand for?
It is an acronym of its four components: KPV, GHK-Cu (the “L” and “O” derive from the blend naming convention rather than the sequences), BPC-157 and TB-500. The vial contains 80mg total across the four sequences.
What is KPV?
A tripeptide — lysine-proline-valine — corresponding to the C-terminal fragment of alpha-MSH. The literature reports anti-inflammatory activity acting intracellularly on NF-κB signalling rather than through melanocortin receptor binding.
Is there research on the KLOW combination specifically?
No substantial controlled research exists on this specific four-way combination at these ratios. The evidence base covers the components individually. Combined behaviour has not been systematically characterised, and that is a genuine limitation.
Should I use a blend or individual peptides for research?
A blend fixes the ratio between components. If the contribution of any single component is a variable of interest in the study design, individual vials are appropriate. A blend suits studies where the combination itself is the object of investigation.
How is a blend reconstituted?
With bacteriostatic water, as with single peptides — but the least stable component governs handling for the whole vial. Dosing by total milligrams does not indicate the quantity of any individual component without the stated ratio.
Are KLOW components legal in the UK?
None are licensed medicines in the UK and none are approved for human consumption. Supply for laboratory research, correctly labelled, is a separate lawful category.
Disclaimer: this content is for educational and research purposes only. None of the compounds described are intended for human use.
